# Sophia Genetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sophia-genetics

- Industry: Healthcare IT
- Headquarters: Switzerland
- Website: www.sophiagenetics.com
- Total disclosed funding: $231M
- Latest round: Series F (Oct 1, 2020)
- Investors on record: 16

## About

Based in Saint Sulpice, Switzerland, and founded in 2011, Sophia Genetics SA operates as a healthcare technology company that provides an analytic software platform for patients with oncology and rare diseases. The company has 415 employees as of July 2021 and was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz. In October 2020, Sophia Genetics SA raised USD 110 million in Series F funding co-led by new investors aMoon and Hitachi Ventures, with participation from other investors. In July 2021, Sophia Genetics SA raised USD 234 million in an IPO, at USD 18 per share on the NASDAQ.

Sophia Genetics develops a cloud-based Software-as-a-Service Sophia DDM platform that uses machine learning, statistical inference, and pattern recognition to collect more accurate radiomic data, characterize genomic variants, and connect patients to appropriate clinical trials. The company's technology is used to treat diseases, including cancer and hereditary disorders, where merging genomic and phenotypic data is critical for supporting discoveries, treatment decisions, and medication development.

The company generated revenue of USD 28.4 million in 2020 and USD 25.4 million in 2019.

Sophia Genetics plans to accelerate the development of new targeted therapies and expand its footprint in the U.S. and Asian markets.

## Funding rounds

- Series F, Oct 1, 2020, $110M — Pictet Group, Eurazeo, Credit Suisse, Endeavour Vision, Generation Investment Management, ACE & Company, Swisscom Ventures, aMoon, Alychlo, Hitachi Ventures, Famille C Invest, Era Funding Administration
- Series E, Jan 4, 2019, $77M — Idinvest Partners, Balderton Capital, Generation Investment Management, Alychlo
- Series D, Sep 13, 2017, $30M — 360 Capital, Balderton Capital, Invoke Capital, Alychlo
- Series B, Jul 8, 2014, $14M — Endeavour Vision, Invoke Capital, Swisscom Ventures

## Investors

- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series B, Series F
- Invoke Capital (https://capitalatlas.ai/funds/invoke-capital) — Series B, Series D
- Swisscom Ventures (https://capitalatlas.ai/funds/swisscom-ventures) — Series B, Series F
- 360 Capital (https://capitalatlas.ai/funds/360-capital) — Series D
- Balderton Capital (https://capitalatlas.ai/funds/balderton-capital) — Series D, Series E
- Alychlo (https://capitalatlas.ai/funds/alychlo) — Series D, Series E, Series F
- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series E
- Generation Investment Management (https://capitalatlas.ai/funds/generation-investment-management) — Series E, Series F
- Pictet Group — Series F
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series F
- Credit Suisse (https://capitalatlas.ai/funds/credit-suisse) — Series F
- ACE & Company (https://capitalatlas.ai/funds/ace-company) — Series F
- aMoon (https://capitalatlas.ai/funds/amoon) — Series F
- Hitachi Ventures (https://capitalatlas.ai/funds/hitachi-ventures) — Series F
- Famille C Invest — Series F
- Era Funding Administration — Series F